Pluri Inc. Logo

Pluri Inc.

Develops placenta-based cell therapeutics using a proprietary 3D cell-expansion platform.

PLUR | TA

Overview

Corporate Details

ISIN(s):
US72942G2030
LEI:
Country:
Israel
Address:
Park Building No. 5, 3508409 Haifa
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pluri Inc., formerly Pluristem Therapeutics, is a biotechnology company that researches, develops, and manufactures cell-based products and therapeutics. The company specializes in its proprietary 3D cell-expansion technology platform, which is used to create solutions for commercial use aimed at improving human well-being and sustainability. Pluri develops products from placenta-based cells for applications across the medical and pharmaceutical industries, often in collaboration with research partners and academic institutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-17 02:42
Director's Dealing
Other Report or Announcement
English 244.9 KB
2025-10-17 02:42
Foreign Filer Report
Other Report or Announcement
English 36.4 KB
2025-10-17 02:40
Remuneration Information
Immediate Report
English 161.6 KB
2025-10-17 02:40
Foreign Filer Report
Immediate Report
English 36.4 KB
2025-10-08 18:02
Regulatory News Service
Pluri Subsidiary Coffeesai and Instituto del Cafe de Chiapas Announce Strategic…
English 146.0 KB
2025-10-08 18:02
Foreign Filer Report
Pluri Subsidiary Coffeesai and Instituto del Cafe de Chiapas Announce Strategic…
English 36.5 KB
2025-09-23 17:54
Director's Dealing
Other Report or Announcement
English 152.3 KB
2025-09-23 17:54
Foreign Filer Report
Other Report or Announcement
English 36.5 KB
2025-09-18 03:08
Registration Form
Other Report or Announcement
English 729.3 KB
2025-09-18 03:08
Foreign Filer Report
Other Report or Announcement
English 36.4 KB
2025-09-18 02:33
Registration Form
Other Report or Announcement
English 315.7 KB
2025-09-18 02:33
Registration Form
Other Report or Announcement
English 36.4 KB
2025-09-18 02:31
Registration Form
Other Report or Announcement
English 317.6 KB
2025-09-18 02:31
Foreign Filer Report
Other Report or Announcement
English 36.4 KB
2025-09-18 01:48
Annual Report
Report of Periodic or Interim Report
English 4.1 MB

Automate Your Workflow. Get a real-time feed of all Pluri Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pluri Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pluri Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Corline Biomedical AB Logo
Develops heparin-based coatings for medical device biocompatibility and regenerative medicine.
Sweden CLBIO
Cosma Spolka Akcyjna Logo
Produces natural hemp supplements and pharmaceutical raw materials for retail & wholesale markets.
Poland COS
COSMO Pharmaceuticals N.V. Logo
Specialty pharma for gastroenterology/dermatology, offering colon treatments & manufacturing services.
Netherlands COPN
Crossject Logo
Develops needle-free auto-injectors for rapid drug delivery in medical emergencies.
France ALCJ
CTC BIO, INC. Logo
Develops pharmaceuticals and feed additives for human and animal health using fermentation tech.
South Korea 060590
Cuorips Inc. Logo
Develops iPS cell therapies, like a cardiomyocyte sheet for severe heart failure.
Japan 4894
curacle co., ltd. Logo
Developing drugs for intractable diseases like diabetes caused by vascular damage and aging.
South Korea 365270
Curevac Logo
Pioneering mRNA technology to create vaccines and therapies for infectious diseases, cancer, and more.
Germany CVAC
Curocell Inc. Logo
Biotech developing enhanced CAR-T therapies for cancer using its OVIS™ platform.
South Korea 372320
Cyfuse Biomedical K.K. Logo Japan 4892

Talk to a Data Expert

Have a question? We'll get back to you promptly.